Where does Intra-cellular Therapies, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Intra-cellular Therapies, Inc. ranks #2,558 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Intra-cellular Therapies, Inc. hold?

Intra-cellular Therapies, Inc. holds 152 US utility patents granted between 2015 and 2025, spanning 15 technology areas.

What is Intra-cellular Therapies, Inc.'s Innovation Score?

Intra-cellular Therapies, Inc. has an Innovation Score of 48.4 out of 100 (top 17% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Intra-cellular Therapies, Inc.'s patent grant rate increasing or decreasing?

Intra-cellular Therapies, Inc.'s recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Intra-cellular Therapies, Inc.'s patents?

Intra-cellular Therapies, Inc.'s patents average 19.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Intra-cellular Therapies, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Intra-cellular Therapies, Inc.

Q: What technology areas does Intra-cellular Therapies, Inc. focus on?

Intra-cellular Therapies, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 128 patents. Grants appear in 15 CPC subclasses total.

USPTO PatentsView assignee record - 152 granted patents across 15 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Intra-cellular ranks #2,558 of 49,997 tracked US assignees by granted-patent volume, with 152 patents across 15 technology areas.

#2,558
of 49,997 US assignees by volume: Top 17%
by Innovation Score (48.4/100): 19.1
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2558 · US Corporation #2,558 · 152 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 152 grants
TOP-DECILE #2,558/49,997
PHOTO-FINISH Bombardier Transport…
CPC-FOCUS A61P · 15 areas
INNOV-PAR 48.4/100
CLAIMS-RICH 19.1 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Bombardier Transportation GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Axcelis · near

48
Columbia Sportswear… · near

48
Intra-cellular… · this assignee

48
Molecular Devices · near

48
The Stanley Works… · near

48
3D Lighting… · lowest

7

What this shows Intra-cellular's Innovation Score is 48.4/100 (top 17% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Intra-cellular's grants concentrate

Intra-cellular Therapies, Inc. is a focused PatentsView assignee: 15 CPC subclasses with 84.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (17 grants) versus a trough of 11 in 2015. By volume, Intra-cellular sits between Bombardier Transportation GmbH and Merlin Technology Inc..

Intra-cellular's three-year grant acceleration

From 2019–2021 to 2022–2024, Intra-cellular Therapies, Inc. moved from 41 to 36 grants (0.88x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,563. See the growth leaderboard.

Bombardier Transp…

152
Fudan University

152
Guardian Industri…

152
Hideep

152
Joyson Safety Sys…

152
Mitsui Kinzoku ACT

152
Mannkind

152
Merlin Technology

152
Intra-cellular Th… ◀

152

What this shows Intra-cellular holds 152 patents at rank #2,558, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Intra-cellular

By rank, the assignees closest to #2,558 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Intra-cellular's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Intra-cellular, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (48 here).

The Stanley Works Israel Ltd. 48 Axcelis Technologies, Inc. 48 Columbia Sportswear North America, Inc. 48 Molecular Devices, LLC 48

Similar claim depth

Nearest assignees by average claims per patent (19.1 here).

Cepheid 19.1 avg Biomet 3i, LLC 19.1 avg Dialog Semiconductor B.V. 19.1 avg UnitedHealth Group Incorporated 19.1 avg

Intra-cellular's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Intra-cellular Therapies, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	11	7.2%
2016	13	8.6%
2017	17	11.2%
2018	12	7.9%
2019	12	7.9%
2020	13	8.6%
2021	16	10.5%
2022	11	7.2%
2023	12	7.9%
2024	13	8.6%
2025partial year	22	14.5%

Which technologies does Intra-cellular Therapies, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 128

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 122

C07D - Heterocyclic Compounds 107

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 18

Y02A - Technologies FOR Adaptation TO Climate Change 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 3

C07C - Acyclic OR Carbocyclic Compounds 3

C07K - Peptides 2

C07J - Steroids 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

B32B - Layered Products, i.e. Products Built-up OF Strata OF Flat OR Non-flat, e.g. Cellular OR Honeycomb, Form 1

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

Top 15 of 15 technology areas

Where it ranks

Overall rank by patents

#2,558

of 49,997 tracked assignees

Innovation Score

48.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Intra-cellular Therapies, Inc.'s patent record in context - here's where to go next.

Intra-cellular Therapies, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 84.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #2,558 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Intra-cellular Therapies, Inc. against Bombardier Transportation GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.